Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 55154-4848

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 55154-4848). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (C9a43df0 Efab 4486 860f 92afdb258c8b 00)

Label for Lansoprazole 30 mg delayed-release orally disintegrating tablets, containing 10 tablets per package. The label includes the NDC 55154-4848 and states storage instructions, phenylalanine content, and warnings about child resistance and institutional use. Manufactured by Teva Pharmaceutical Ind. Ltd., Israel, and distributed by Cardinal Health.*

FDA Label Image

Chemical Structure (Image 1)

Chemical structure of lansoprazole, an oral delayed-release orally disintegrating tablet. The diagram shows the molecular arrangement with key elements, including benzimidazole, sulfoxide, and trifluoromethyl groups, associated with lansoprazole's chemical identity.*

FDA Label Image

Figure-01 (Image 2)

Line graph showing mean severity of day heartburn over time for evaluable patients in a study. The y-axis measures mean severity from 0 (none) to 3 (severe), while the x-axis shows days from start of treatment, ranging from -5 to 60. Three groups are compared: placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily, with lansoprazole groups showing notably lower heartburn severity than placebo over time.*

FDA Label Image

Figure-02 (Image 3)

A line graph showing the mean severity of night heartburn over days from the start of treatment in a study. The graph compares placebo, lansoprazole 15 mg once daily, and lansoprazole 30 mg once daily. The y-axis measures mean severity of night heartburn (0 to 3 scale), and the x-axis shows days from treatment start (up to 60 days). Lansoprazole groups show lower severity compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.